FDA Approves Lipfendra as First Oral Therapy to Lower LDL Cholesterol in Adults
The U.S. Food and Drug Administration (FDA) has granted approval for Lipfendra (enlicitide), a groundbreaking oral therapy designed to lower low-density lipoprotein cholesterol (LDL-C) in adults suffering from high cholesterol. This medication is intended to be used in conjunction with diet and exercise, particularly for those with high cholesterol levels or those diagnosed with heterozygous familial hypercholesterolemia (HeFH). Lipfendra is administered as a once-daily oral tablet.
Hypercholesterolemia is characterized by elevated levels of LDL-C, often referred to as "bad" cholesterol. While cholesterol is essential for various bodily functions, excessive LDL-C can lead to serious health issues. Over time, high levels of LDL-C can infiltrate the arterial walls, where they combine with inflammatory cells to form plaques. This plaque buildup can narrow arteries and impede blood flow, increasing the risk of severe cardiovascular events such as heart attacks and strokes.
Many individuals with high cholesterol may remain asymptomatic, often unaware of their condition until they undergo a lipid panel blood test. Factors contributing to high cholesterol include dietary choices, lack of physical activity, obesity, and genetic predisposition.
Treatment options for high cholesterol have traditionally included statins, ezetimibe, and PCSK9 inhibitors. However, Lipfendra stands out as the first oral medication that targets and blocks the PCSK9 protein, which plays a crucial role in cholesterol regulation.
The efficacy and safety of Lipfendra were established through two randomized, double-blind, placebo-controlled clinical trials involving 3,207 adults diagnosed with severe hypercholesterolemia, including both those with and without HeFH. Participants were already receiving maximally tolerated statin therapy. The primary outcome measured was the percentage change in LDL-C levels from baseline to Week 24, comparing results between the Lipfendra and placebo groups.
In the first trial, which focused on adults with a history of atherosclerotic cardiovascular disease (ASCVD) or those at high risk for ASCVD, the average baseline LDL-C was recorded at 96 mg/dL. The results showed a significant average percentage reduction of 56% in LDL-C levels for the Lipfendra group compared to the placebo group at Week 24.
The second trial specifically targeted adults with HeFH, where the average baseline LDL-C was 119 mg/dL. Participants in the Lipfendra group experienced an average reduction of 59% in LDL-C levels by Week 24 compared to those receiving placebo.
Adverse reactions associated with Lipfendra were generally comparable to those observed in the placebo group. However, in the HeFH trial, diarrhea and dizziness were reported more frequently among participants taking Lipfendra than those on placebo. Notably, similar proportions of patients in both groups discontinued treatment due to adverse reactions.
The approval of Lipfendra was granted under the FDA's Priority Review designation, emphasizing its potential impact on the treatment landscape for high cholesterol. Merck Sharp & Dohme LLC is the company responsible for bringing this innovative therapy to market.




